In this follow-up to the previous Doc Gumshoe missive about cancer, entitled “Cancer 2023 – What’s Happening in the Combat Zone,” which posted on July 18, we’ll be discussing several general types of cancer – brain, lung, ovarian, breast, liver, and cancer caused by obesity. In each case, however, there are special conditions associated with […]
6 Comments Read MoreArticles
Cancer 2023 – Second Installment
Cancer 2023: What’s Happening in the Combat Zone?
Just over 50 years ago, President Richard M. Nixon signed into law the National Cancer Act of 1971, which established the National Cancer Institute. Cancer had become the second leading (after heart disease) cause of death in the US in 1970. The National Cancer Institute (NCI) from its establishment had broad powers, including the creation […]
26 Comments Read MoreMarch 2023 Miscellany
Osteoporosis Update (Part Two)
Odd & Ends – October 2022
Stansberry Venture’s “Major Announcement” — What are the Three Companies facing a Wave of Money?
New ads pitch a special report called "Three Ways to Make Triple-Digit Gains on Flash-Radioimmunotherapy," and we've got the Thinkolator results ... plus, a note about the also-teased "Incredible Weight-Loss Drug"
22 Comments Read MoreFollowing Up on Your Suggestions – September 2022
Updates on Alzheimer's Disease, Anti-Inflammatories, Prostate Cancer, Vitamin D and more...
20 Comments Read MoreMarch 2022 Bulletins — Brief, but Relevant
Doc Gumshoe looks at infections, weight-loss drugs, cataracts and dementia, Vitamin D supplements and more...
23 Comments Read MoreCOVID-19: Keeping Up With the Current State of the Pandemic
This will be the thirteenth Doc Gumshoe pronouncement on the COVID-19 pandemic. Lucky or unlucky, I have no idea, but let’s get on with it. To the question “Where are we now?” the answer depends enormously on exactly where, geographically, we are. The differences in the new case and fatality rates in among the different […]
62 Comments Read MoreWhat’s up with Stansberry Venture’s “Major FDA Announcement” Pitch?
Sniffing out the teased Obesity stocks from Dave Lashmet's Stansberry Venture Technology
14 Comments Read MoreWhat’s that “First and Best Drugs” Alzheimer’s Stock for 300% gains?
What's teased as the latest Alzheimer's Disease recommendation from Dave Lashmet for Stansberry's Investment Advisory?
13 Comments Read MoreHodge’s pitch: “The first machine in the world that can detect this deadly virus on site is being rushed to market. “
What's this machine that Early Advantage teases can send a little stock from $1 to $20?
35 Comments Read MoreAlzheimer’s Disease: 2019 Refresher and Updates
Combating Cancer: The Current Battle Plan
Rapid Response: The Israeli Cure for All Cancers? And a Postscript on Opioids
What set me off on this rant was the very first comment on the piece that posted on January 31st, “Looking Backward – And a Peek in the Other Direction.” Here’s the comment: “Thanks, Doc. Hope you will comment on the news out of Israel this week: https://www.jpost.com/HEALTH-SCIENCE/A-cure-for-cancer-Israeli-scientists-say-they-think-they-found-one-578939” Naturally, I looked, and what I found […]
39 Comments Read MoreLooking Backward – And a Peek in the Other Direction
Doc Gumshoe looks at the state of cancer treatment... and some of the interesting drug approvals from 2018
14 Comments Read MoreCancer Treatment 2018: Looking Towards the Future
Most of the attention in the media is now focused on the several forms of cancer treatment grouped under the flattering term “Precision Medicine.” I find that the term raises my skepticism index just a bit; it’s like eating establishments labeling themselves “Gourmet Restaurants,” the implication being that joints not so identified are just […]
23 Comments Read MoreCancer: The Lay of the Land in 2018
Putting the name of this imperious disease in the title of my homily places a weighty responsibility on me. Who am I to attempt to put forth relevant information and sensible opinions on this topic, the mere mention of which makes most normal folk distinctly uneasy? But I probably pay more attention to […]
34 Comments Read MoreAlzheimer’s Disease 2018: The Lay of the Land
March 2018 Catch Up: What’s Been Happening in the Pharm World?
Navellier’s “Five Times Your Money in a Stock That Stops Cancer”
Oncotutorial
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
4,732 Comments Read MoreCan this $5 Company rise 16,000% and “Eradicate Zika” like Sid Riggs teases?
Conflict Diamonds
Two Flubs and a Big Question Mark
Alzheimer’s Wrap-Up
Alzheimer’s Disease: Current Options and Possible Treatment Approaches
The Last Samurai Biotech
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]
1,435 Comments Read MoreLichtenfeld: “I See a 4,150% Earnings Setup in This $6 Biotech”
This article originally ran on January 12… the teaser pitch was still being circulated heavily last week, and the stock released earnings on February 3 that disappointed investors, bringing shares down about 15% (it was teased as a “$7 biotech,” and briefly $8, before then). The original Jan. 14 “special event” catalyst teased by Lichtenfeld, […]
26 Comments Read MoreThe Long Case for Receptos
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Gumshoe Irregulars. He has agreed to our trading restrictions, he chooses his own topics, and his words and opinions are his own. Enjoy!] OK, admit it….how many of you have seen the campy films of Baltimore director John Waters? The ones starring the […]
885 Comments Read MoreCancer Care: Where Are We and Where Are We Headed?
[ed note: Michael Jorrin is a longtime medical writer (not a doctor) who covers health and medical topics and trends for our readers, generally without an investment thesis. His words are his own, enjoy!] In the Doc Gumshoe blog about cancer that appeared in June of 2013 (you can check it out here), I commented […]
36 Comments Read MoreDawn of the Planet of the TLOGlodytes!
What’s the “Ideal Retirement Booster” (IRB) from Oxford Club?
The Gain from Pain Mainly Explained: Fire Walk with Me
Will This Unknown Boston Biotech Make Present Surgical Techniques Obsolete?
Special Update on Cellceutix
[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
308 Comments Read MoreYellow Eyes, White Powders, and an Unknown Nordic Biotech That May Green Things Up for Investors
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own. Enjoy!] In the Saturday morning Looney Tunes many of us saw as children, one trope always stuck with me: that of the grand piano falling from way up high and crashing, splintering itself. There’s a […]
1,033 Comments Read MoreHepatitis with a C
Is Any Big Pharma Outfit NOT Interested in Buying This Little-Known Biotech?
Antibiotics Don’t Get No Respect, But You Can Still Profit From Them
From Rheumatism to RA: A Basic Change in Understanding
Current Clinical Trials in Alzheimer’s Research
Alzheimer’s Disease: Are There Any Glimmers of Light?
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
39 Comments Read MoreWhat’s Happening in Cancer Treatment? Are We Making Progress, or Are We Stuck?
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
57 Comments Read More“Stocks That Can Benefit from the New Bird Flu Outbreak”
The Rest of those “Extra Paychecks” from Leeb’s “MCR Plan”
As promised, we’re following up with the rest of the picks that Stephen Leeb (sorry, Dr. Stephen Leeb) is pitching as his “MCR” Plan. If you missed our first entry as we began demystifying this particular ad, you can see it here — the short version is, he’s touting dividend paying stocks in the medical […]
1 Comment Read MoreWe use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
No comments.